Indaptus Therapeutics, Inc. Common Stock
$3.55
Market Cap
$473.01M
Shares Outstanding
133.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 4, 2021
Round Lot
100
Locale
US
Day Open
$3.85
Day High
$4.09
Day Low
$3.51
Volume
1.16M
VWAP
$3.71
Prev Close
$3.93
Transactions
--
Acc. Volume
--
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Indaptus Therapeutics, Inc. Common Stock (INDP) closed the 2026-09-18 session at $3.55, down 9.67% versus the previous close (-0.38). The stock opened at $3.85 and traded between $3.51 and $4.09 during that session. Session trading volume was 1.2M shares. The volume-weighted average price (VWAP) is $3.71.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Indaptus Therapeutics, Inc. Common Stock has a market capitalization of $473.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. INDP is listed on the XNAS exchange. The company employs approximately 5 people. Indaptus Therapeutics, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2021-08-04.
On this page you can find market INDP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.